How to Prepare a Freedom‑to‑operate (FTO) Opinion in Canada (2026), Pharma & Biotech: Step‑by‑step

Before a pharmaceutical or biotech company can manufacture, sell, or use a new product in Canada, it must determine whether doing so would infringe any enforceable Canadian patent, and that determination takes the form of a freedom‑to‑operate opinion. Understanding how to prepare a freedom to operate opinion in Canada is essential for in‑house counsel, R&D leaders, investors, and founders who need a clear, jurisdiction‑specific risk assessment before committing capital or filing regulatory submissions. The FTO process Canada follows is shaped by the Patent Act (R. S. C. 1985, c. P‑4), Federal Court claim‑construction jurisprudence, and, as of March 2026, CIPO’s revised Practice Notice on Patentable Subject‑Matter.

This guide walks through each stage of the process, the documents needed, realistic timelines, cost bands, and the 2026 regulatory changes that every pharma and biotech FTO must now address.

Overview of the Freedom‑to‑Operate Opinion Process and Who It Applies To

A freedom to operate opinion Canada (sometimes called a “clearance opinion” or “right‑to‑use opinion”) is a legal analysis that evaluates whether a specific product, process, or method, as described by its actual technical features, would infringe one or more valid, enforceable Canadian patent claims. It is not a patentability opinion (which asks whether your invention is new and inventive) and it is not a validity opinion (which asks whether an existing patent should have been granted). An FTO opinion is narrower and more practical: it asks whether you can operate without infringing.

In the pharma and biotech sector, the analysis is particularly complex. Products may encompass small‑molecule compounds, biologics, antibody‑drug conjugates, diagnostic methods, drug‑delivery systems, and manufacturing processes, each raising different claim‑construction challenges under section 2 of the Patent Act, which defines “invention” and sets the outer boundary of patentable subject matter. Subsection 27(8) further specifies that no patent shall be granted for certain subject matter, including methods of medical treatment in certain circumstances. These statutory boundaries interact with judicially‑excluded categories (abstract ideas, scientific principles, purely mental steps), making purposive claim construction the linchpin of every FTO analysis.

The standard outputs of a Canadian pharma FTO are: a searchable patent citation set, a claim‑map table linking each relevant claim element to the corresponding product feature, a banded risk conclusion (clear / low / moderate / high risk), and recommended next steps, which may include design‑around options, licence negotiations, patent challenge strategies, or a decision to proceed with documented risk acceptance. The opinion is typically commissioned by in‑house patent counsel, a general counsel preparing for board or investor due diligence, an acquirer during M&A, or an R&D leader seeking go/no‑go authority before clinical‑stage investment.

Eligibility and Prerequisites for Commissioning an FTO Opinion in Canada

Any entity that intends to make, use, sell, or import a pharmaceutical or biotech product in Canada may commission a freedom to operate opinion. There is no statutory eligibility threshold; the decision is driven by commercial risk management. Typical commissioners include Canadian operating companies, foreign parent companies with Canadian subsidiaries, contract manufacturers supplying the Canadian market, incoming venture‑capital or private‑equity investors performing technical due diligence, and generic or biosimilar manufacturers evaluating market entry.

Foreign companies that do not have a Canadian establishment can and routinely do commission FTOs. However, the opinion must be prepared, or at a minimum supervised and signed, by Canadian patent counsel qualified to practise before the Federal Court, because Canadian claim construction rules, statutory defences, and procedural mechanisms (including PM(NOC) proceedings) differ materially from those in the United States, Europe, or other jurisdictions. Engaging a Canadian patent agent alone may be insufficient where litigation risk is significant; a patent litigator adds claim‑construction depth informed by Federal Court and Federal Court of Appeal decisions.

Essential Inputs from R&D / Product Team

Before counsel can begin the FTO process, the following technical inputs should be assembled:

• Product description. Full characterisation of the active ingredient, formulation, indication, and mechanism of action.
• Prototype / test data. Any bench‑scale, pilot, or clinical data that confirms how the product actually works (as distinct from how it might theoretically work).
• Composition and formulation details. Excipients, carrier systems, concentrations, and delivery form.
• Manufacturing steps. Process flow diagrams, reaction schemes, purification steps, and any proprietary methods.
• Target claims and features. If the product team has already identified specific competitor patents of concern, list them with claim numbers.
• Prior art already known. Internal search results, competitor publications, or patent landscapes previously reviewed.

Step‑by‑Step FTO Process in Canada: How to Prepare a Freedom to Operate Opinion

The FTO search steps and analysis can be divided into eight sequential stages. The table below summarises who is responsible and how long each stage typically takes; the detailed discussion beneath it explains the substantive work at each stage.

Step 1, Define scope and instructions

External counsel, in‑house counsel, and the lead scientist hold a kickoff meeting to define the exact product features to be searched, the territories in scope (Canada is mandatory; additional jurisdictions may be added), and the client’s risk tolerance. The engagement letter should specify whether the opinion will cover only granted Canadian patents or also published applications, whether it will address utility models or industrial designs (rare in pharma but relevant for device combinations), and whether the client wants a full litigation‑risk assessment or a preliminary landscape scan. Recording these assumptions up front protects both client and counsel and prevents scope creep.

Step 2, Technical intake and claim identification

Counsel converts the product features into searchable technical claim elements. For a biologic, this might mean identifying the amino‑acid sequence (FASTA format), CDR regions, target antigen, expression system, and purification method. For a small molecule, it means the Markush structure, salt form, crystalline polymorph, and synthetic route. Each element becomes a column header in the claim‑map table that will be populated later. This step requires close collaboration between a technically trained patent professional and the R&D team to ensure no material product feature is overlooked.

Step 3, Comprehensive patent and non‑patent literature search

A professional patent searcher runs structured searches across multiple databases. For Canada‑focused FTO work, the minimum database set typically includes the Canadian Patent Database (CIPO), WIPO Patentscope, Espacenet (EPO), USPTO full‑text and image databases, Derwent Innovation, and Google Patents. Sequence and structure searches use BLAST (NCBI), PatSeq (Lens.org), and commercial chemistry tools such as SciFinder or Reaxys. Classification‑based filters (CPC and IPC codes) narrow the results, while keyword and Boolean operators refine them further. Non‑patent literature sources, PubMed, clinical‑trial registries (ClinicalTrials.gov, Health Canada Clinical Trials Database), and regulatory approval documents, help identify products and processes that may be the subject of undisclosed patent applications. The searcher exports raw results in CSV or PDF for reproducibility and appendix inclusion.

Step 4, Initial screening and relevance triage

The raw search output is reviewed and each result is tagged as high, medium, or low relevance against the product’s claim elements. High‑relevance hits are patents or applications whose independent claims appear to read on one or more product features. Medium‑relevance hits have overlapping subject matter but narrower claims or uncertain applicability. Low‑relevance hits are retained in the appendix for completeness but are not mapped in detail. This triage step reduces the universe of patents that need full claim construction from potentially thousands to a manageable set, typically between five and fifty for a single pharma product.

Step 5, Purposive claim construction and claim mapping

This is the analytical core of any freedom to operate opinion Canada. Under Canadian law, patent claims must be construed purposively, informed by the patent specification as a whole and read through the eyes of a person skilled in the art. The Supreme Court of Canada has consistently held that claims should be given neither the broadest possible nor the narrowest possible construction, but rather the construction that the inventor intended, taking account of the description, drawings, and prosecution history.

Since March 2026, CIPO’s revised Practice Notice on Patentable Subject‑Matter requires that claim construction expressly address the “physicality” of the claimed invention and whether it falls within a judicially‑excluded category, particularly relevant for diagnostic method claims, computer‑implemented dosing algorithms, and AI‑driven drug‑discovery tools.

The claim‑map table is the principal deliverable of this step. It systematically compares each element of a relevant patent claim against the corresponding feature of the client’s product. An illustrative excerpt for claim mapping in pharma and biotech might look like this:

Where a claim term is ambiguous, counsel should record alternative constructions and explain how each construction affects the infringement analysis. This practice is now particularly important in light of Dusome v Canada (2025 FC 1809), which criticised CIPO’s prior approach and underscored the need for explicit, well‑reasoned purposive construction.

Step 6, Legal analysis and infringement risk opinion

Senior patent counsel reviews the completed claim maps and assigns a risk level to each identified patent: clear (no claim element reads on the product), low (one or more elements arguably differ), moderate (infringement depends on unresolved claim‑construction questions or doctrine‑of‑equivalents arguments), or high (all claim elements appear to be met). The analysis considers patent term and maintenance status (checking CIPO maintenance fee records), assignment and ownership records, any PM(NOC) listing for the relevant drug, and the availability of statutory defences such as the regulatory‑review exception under section 55. 2(1) of the Patent Act.

An FTO opinion does not prevent a patentee from commencing PM(NOC) proceedings or an infringement action, but it does provide the client with a documented basis for its commercial decision.

Step 7, Draft the opinion report

The FTO report template should follow a standard structure: front‑page executive summary (risk level, key patents, recommended actions), scope and assumptions section, search methodology (databases, dates, operators), claim‑mapping appendix, legal analysis per patent, limitations clause (date of search, disclaimer of warranty, reliance restrictions), and recommended next steps. The limitations clause is critical: it should state the exact search cut‑off date, note that newly filed applications not yet published are outside the scope, and recommend a follow‑up search schedule.

Step 8, Delivery, Q&A, and follow‑up search plan

Counsel delivers the opinion and holds a Q&A session with the in‑house team to walk through moderate‑ and high‑risk findings. Version control is important, every iteration should be date‑stamped and labelled (Draft v1, Final v1, Update v2). A post‑opinion watch plan should be established: patent watch services monitor newly published applications and granted patents in the relevant CPC/IPC classes and notify counsel of potential new risks. Industry observers expect quarterly updates to be the emerging standard for products approaching regulatory filing or launch.

Required Documents and Information for a Canadian FTO Opinion

Assembling the correct documents before engaging counsel is the single most effective way to control both cost and quality. The table below lists the documents needed for a robust pharma or biotech FTO in Canada.

When assembling the FTO report template, counsel should organise these inputs into a structured appendix so that any future reviewer, including litigation counsel, a potential acquirer, or a regulatory authority, can trace every conclusion back to its evidentiary source. The claim‑mapping appendix is particularly important: it should be formatted as a table that can be updated as the product evolves or as new patents publish.

Timeline and Key Deadlines for the FTO Process in Canada

For a single‑country Canada FTO covering a typical small‑molecule pharmaceutical product, the end‑to‑end timeline from kickoff to final signed opinion is approximately four to eight weeks. Complex biologics, antibody‑drug conjugates, or products that implicate large patent families can extend this to ten to fourteen weeks. The timeline below provides milestone benchmarks that in‑house teams can use for project planning.

Three deadlines require particular attention. First, the search cut‑off date must be recorded in the opinion, any patent application filed after that date is outside scope, and the opinion’s validity degrades over time. Second, patent term expirations should be checked against CIPO grant and maintenance‑fee records: a patent that will expire before the client’s planned launch may be deprioritised. Third, for products subject to PM(NOC) proceedings, counsel should check whether relevant patents are listed on the Patent Register and whether any stay periods from ongoing litigation could affect market entry timing.

Cost of an FTO Opinion in Canada: Fees and Staged Pricing

The cost of FTO opinion work in Canada varies substantially depending on the technology, the number of patent families implicated, and the level of litigation‑awareness required. A staged pricing model allows clients to manage spend by committing to each phase incrementally.

Key cost drivers include the number of relevant patent families (each requires individual claim mapping), the need for sequence or structure searches (which require specialised databases and expertise), whether the opinion must address PM(NOC) exposure, and whether the client needs the opinion to be “litigation‑ready”, that is, drafted with a view to being relied upon in Federal Court proceedings. Professional fees for FTO work are generally deductible as R&D or legal expenses for Canadian tax purposes, but companies should confirm the treatment with their tax adviser.

What Changes in 2026: CIPO Practice Notice and Dusome Implications for FTO Opinions

Two developments in 2026 have materially changed how a freedom to operate opinion Canada should be prepared.

CIPO’s March 2026 Practice Notice on Patentable Subject‑Matter supersedes earlier sections of the Manual of Patent Office Practice (MOPOP) and introduces a revised analytical framework for determining whether claimed subject matter constitutes an “invention” under section 2 of the Patent Act. The Practice Notice requires patent examiners, and, by extension, practitioners assessing third‑party patents, to apply purposive construction before assessing patentable subject matter, and to evaluate whether the construed claims possess “physicality” (i. e. , whether they produce a physical effect or change, or involve a physical implementation).

This is directly relevant to pharma FTOs involving diagnostic method claims, personalised‑medicine algorithms, computer‑implemented dosing regimens, and AI‑assisted drug‑discovery methods: any FTO that identifies such claims must now explicitly address whether, under the revised CIPO framework, those claims would be considered valid subject matter at all.

The Practice Notice was itself prompted by the Federal Court’s decision in Dusome v Canada (2025 FC 1809), which found fault with CIPO’s earlier “actual invention” analysis and directed CIPO to reconsider its approach. Industry observers expect the practical effect to be increased uncertainty around claims at the boundary of patentable subject matter, particularly medical diagnostic methods and computer‑implemented inventions. For FTO practitioners, the drafting implication is clear: every 2026 opinion should include a dedicated section that (a) identifies which CIPO Practice Notice paragraphs were considered, (b) explains how purposive construction was applied to each claim at issue, and (c) flags any subject‑matter uncertainty and presents alternative constructions with corresponding risk outcomes.

Common Pitfalls in Canadian FTO Opinions and How to Avoid Them

• Vague technical intake. If the product description is incomplete or imprecise, the claim‑mapping step will miss critical features. Avoid this by using the checklist in the eligibility section above and requiring R&D sign‑off on the product specification before the search begins.
• Insufficient claim mapping. Summarising a patent’s abstract instead of mapping each independent claim element to a product feature is the most common quality failure. Require a structured claim‑map table for every high‑relevance patent.
• Ignoring CIPO 2026 subject‑matter guidance. Opinions that do not address the March 2026 Practice Notice risk missing a viable non‑infringement or invalidity argument. Include a dedicated 2026 analysis section in every report.
• Overconfident clearance conclusions. Stating “no risk” is almost never appropriate. Use a banded risk scale and document the assumptions behind each rating.
• Failure to record assumptions and search cut‑off dates. Without a documented cut‑off date, the opinion’s shelf life is undefined. State the date explicitly and recommend a follow‑up schedule.
• Not watching newly issued patents. A one‑time search becomes stale within months. Establish an ongoing patent watch service, particularly in fast‑moving therapeutic areas.

Sources

1. Canadian Intellectual Property Office, March 2026 Practice Notice on Patentable Subject‑Matter
2. Patent Act (R.S.C. 1985, c. P‑4), Justice Laws (Consolidated)
3. DLA Piper, What the Federal Court Decision in Dusome v Canada Means for Patentable Subject Matter
4. WIPO, Freedom to Operate Toolkit
5. Smart & Biggar, What Is a Freedom to Operate Analysis?
6. Practical Law / Thomson Reuters, FTO Toolkit (Canada)
7. DLA Piper, CIPO’s Revised Approach to Patentable Subject Matter in the Dusome Application
8. McMillan, Updated Guidance from CIPO on Patentable Subject Matter